{"page":{"totalFilteredElements":335},"studies":[{"active":true,"description":"Netzwerk Onkologie (NO) - Therapiebegleitende Darstellung des Versorgungsalltages in der integrativen Onkologie

DRKS: DRKS00013335

Retrospektiv
","eudractNumber":null,"id":12273,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-22T08:21:56+02:00","shortTitle":"Netzwerk Onkologie (NO)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL) IOM-100361","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"}],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"
Peripheral Neuropathy in Patients receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma
","eudractNumber":null,"id":11734,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06657157","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-01-29T08:54:41+01:00","shortTitle":"P-Evolution","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A Phase 2, Open-Label, Parallel Cohort Study of\nSubcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or\nMetastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]

","eudractNumber":"2022-000526-21","id":8484,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT05498428","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-03-01T11:55:23+01:00","shortTitle":"PALOMA-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Patientendatenintegrationsplattform der Pancreatic Cancer Alliance Bavaria (PCAB)","eudractNumber":null,"id":10521,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-05-26T12:31:40+02:00","shortTitle":"PCAB (Pankreasregister)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":10857,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-01T08:48:22+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4239,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-07-01T10:24:09+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":4307,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-01-03T08:40:46+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":10618,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-08-05T11:57:37+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

DRKS00010774
","eudractNumber":null,"id":9703,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-15T10:33:43+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]}]}